You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

About Ovarian Cancer

Ovarian cancer is rare but deadly1

A Diagnosis of Advanced-Stage Ovarian Cancer Often Leads to Poor Prognosis2

+ Click to Zoomx Exit Zoom

+ Click to Zoomx Exit Zoom

Despite optimal surgical outcomes and high response rates to 1L platinum-based chemotherapy, the outlook in advanced ovarian cancer remains poor3,4

Without maintenance, PFS shortens with each recurrence5

+ Click to Zoomx Exit Zoom

There is a need for a maintenance therapy that3,6-8

Need for maintenance therapy chart

PROLONGS

progression-free survival
Need for maintenance therapy chart

EXTENDS

PARP inhibitor therapy to more women9-11
Need for maintenance therapy chart
Offers

CONVENIENT

once-daily, oral dosing

1L, first-line; BRCA, breast cancer susceptibility gene; CI, confidence interval; PARP, poly (ADP-ribose) polymerase; PFS, progression-free survival.

1L, first-line; BRCA, breast cancer susceptibility gene; CI, confidence interval; PARP, poly (ADP-ribose) polymerase; PFS, progression-free survival.

Efficacy data

EFFICACY DATA

View efficacy data for all indications

See the Data

STUDY DESIGN

See the PRIMA clinical trial design

View Trial Info
Back to Top

References: 1. American Cancer Society. Cancer Facts & Figures 2019. Atlanta, GA: American Cancer Society; 2019. 2. SEER Cancer Stat Facts: ovarian cancer. National Cancer Institute website. https://seer.cancer.gov/statfacts/html/ovary.html. Accessed September 8, 2020. 3. Lorusso D, Mancini M, Di Rocco R, Fontanelli R, Raspagliesi F. The role of secondary surgery in recurrent ovarian cancer. Int J Surg Oncol. 2012;2012:613980. Doi:10.1155/2012/613980. 4. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review. 1975-2016. Bethesda, MD: National Cancer Institute. https://seer.cancer.gov/csr/1975_2016/, based on November 2019 SEER data submission, posted to the SEER website, April 2020. Accessed September 8, 2020. 5. Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605-2612. 6. Matulonis UA. Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol. 2018;16(6):426-437. 7. Banerjee SN, Lord CJ. First-line PARP inhibition in ovarian cancer — standard of care for all? Nat Rev Clin Oncol. 2020;17(3):136-137. 8. Krikorian SA, Shamim K. Adherence issues for oral antineoplastics: a focus on prevention and management of side effects related to targeted therapies. Am J Lifestyle Med. 2013;7(3):206-222. 9. ZEJULA (niraparib). Prescribing Information. GlaxoSmithKline; 2020. 10. Lynparza (olaparib). Prescribing Information. AstraZeneca Pharmaceuticals LP; 2020. 11. Rubraca (rucaparib). Prescribing Information. Clovis Oncology, Inc; 2020.